Concr

Concr is a London-based precision oncology company that applies Bayesian AI adapted from astrophysics to predict individual cancer treatment responses.

Its platform integrates genomic, imaging and clinical data to model tumour biology with minimal input, treating each patient as an analogue of a galaxy with unobservable properties.

Validated through Innovate UK-funded collaborations with the Institute of Cancer Research and the Royal Marsden, the company is running an observational trial in triple-negative breast cancer.